Impact of aspirin dose according to race in secondary prevention of atherosclerotic cardiovascular disease: a secondary analysis of the ADAPTABLE randomised controlled trial.

ABSTRACT:

Objectives

To evaluate whether the effectiveness and safety of low (81 mg daily) versus high-dose (325 mg daily) aspirin is consistent across races among patients with established atherosclerotic cardiovascular disease (ASCVD).

Design

A secondary analysis of the randomised controlled trial ADAPTABLE was performed.

Setting

The study was conducted in 40 centres and one health plan participating in the National Patient-Centred Clinical Research Network (PCORnet) in the USA.

Participants

Among 15 076 participants with established ASCVD, 14 096 had self-reported race available and were included in the analysis. Participants were divided according to self-reported race as Black (n=1311, 9.3%), White (n=11 990, 85.1%) or other race (n=795, 5.6%).

Interventions

SUBMITTER: Marquis-Gravel G 

PROVIDER: S-EPMC11407226 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature